| Title |
Pharmacotherapy for uveitis: current management and emerging therapy
|
|---|---|
| Published in |
Clinical Ophthalmology, September 2014
|
| DOI | 10.2147/opth.s47778 |
| Pubmed ID | |
| Authors |
Robert J Barry, Quan Dong Nguyen, Richard W Lee, Philip I Murray, Alastair K Denniston |
| Abstract |
Uveitis, a group of conditions characterized by intraocular inflammation, is a major cause of sight loss in the working population. Most uveitis seen in Western countries is noninfectious and appears to be autoimmune or autoinflammatory in nature, requiring treatment with immunosuppressive and/or anti-inflammatory drugs. In this educational review, we outline the ideal characteristics of drugs for uveitis and review the data to support the use of current and emerging therapies in this context. It is crucial that we continue to develop new therapies for use in uveitis that aim to suppress disease activity, prevent accumulation of damage, and preserve visual function for patients with the minimum possible side effects. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 128 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 128 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 16 | 13% |
| Student > Master | 16 | 13% |
| Student > Bachelor | 11 | 9% |
| Student > Postgraduate | 10 | 8% |
| Other | 8 | 6% |
| Other | 32 | 25% |
| Unknown | 35 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 63 | 49% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 5% |
| Biochemistry, Genetics and Molecular Biology | 4 | 3% |
| Agricultural and Biological Sciences | 4 | 3% |
| Unspecified | 3 | 2% |
| Other | 13 | 10% |
| Unknown | 35 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 21. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 April 2021.
All research outputs
#1,805,898
of 25,371,288 outputs
Outputs from Clinical Ophthalmology
#108
of 3,712 outputs
Outputs of similar age
#18,428
of 248,664 outputs
Outputs of similar age from Clinical Ophthalmology
#1
of 33 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,712 research outputs from this source. They receive a mean Attention Score of 4.9. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 248,664 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 33 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.